Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
You may also be interested in...
IDWeek 2022 Notebook: Entasis Bolsters Case For SUL-DUR Antibiotic Combo
Entasis is hoping for a pathogen- rather than location-specific indication for sulbactam-durlobactam (SUL-DUR) in the US. Gilead’s Veklury remains a standard-of-care COVID-19 treatment. Summit claims further analysis of failed ridinilazole Phase III study shows recurrence advantage versus vancomycin.
Chimerix Scores Smallpox Preparedness Contract With BARDA
Deal Snapshot: The contract for Tembexa, which builds on an existing deal between Chimerix and Emergent BioSolutions, illustrates lucrative potential opportunities for emergency preparedness.
Alcon Buys Aerie, Reaffirming Commitment To Pharma Space
With the $770m acquisition, Alcon will gain two commercial eye drop products for glaucoma and a Phase III candidate for dry eye.